ArticleBone marrow transplantation2009
Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9.
Article in Bone marrow transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Genetic variants associated with inflammatory bowel disease and gut graft-versus-host disease.Blood advances · 2021Article
- Targeting Toll-Like Receptors for Cancer Therapy.Targeted oncology · 2018Article
- Sensing danger: toll-like receptors and outcome in allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2017Review
- Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases.International journal of molecular sciences · 2016Review
- Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.Frontiers in immunology · 2016Review
- Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.Mucosal immunology · 2015Review
- Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.Frontiers in immunology · 2015Review
- Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes.Bone marrow transplantation · 2014Article
- A non-interventional study of the genetic polymorphisms of NOD2 associated with increased mortality in non-alcoholic liver transplant patients.BMC gastroenterology · 2014Article
- The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation.Frontiers in immunology · 2014Review
- Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses.International journal of hematology · 2013Review
- A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT.Bone marrow transplantation · 2012Article
- Association analysis of the NOD2 gene with susceptibility to graft-versus-host disease in a Japanese population.International journal of hematology · 2011Article
- Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors.Bone marrow transplantation · 2011Article
- The role of bacteria and pattern recognition receptors in GVHD.International journal of inflammation · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toll-like receptor 9 (TLR9) is part of the innate immune system, which is activated by CpG oligonucleotides (ODNs) and produces potent Th1-type innate and adaptive immune responses. It is reported that TLR9 gene variants, T1486C and T1237C, are associated with a reduced TLR9 expression compared with the wild-type gene. In two cohort analyses, we evaluated the influence of these gene variants on the outcome of transplant in 413 patients and donors. A retrospective analysis of the first cohort (n=293) showed that the homozygous CC gene variant of TLR9 (1486) compared with TC/TT gene variants was significantly associated with a markedly improved 5-year TRM (11.7 versus 36.4%, P<0.003), 5-year OS (86.1 vs 48.3%, P<0.001) and a lower relapse rate (13.2 vs 33.3%, P<0.007), whereas the occurrence of acute GVHD was not different. A prospectively performed analysis of the second cohort (n=120) and multivariate analyses confirmed the influence of the CC gene variant on these end points. Compared with patients with TC/TT gene at position 1486 of TLR9, patients with the homozygous CC gene variant had a lower TLR9 mRNA expression and a delayed T-cell immune reconstitution after transplant, which might prevent them from overwhelming immune responses as sepsis or systemic inflammatory response syndrome (SIRS) associated with an increased TRM. In vitro studies using CpG-rich ODNs showed an upregulation of TLR9 expression in cell lines with CC gene variant, but not in cell lines with wild-type gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.